Halozyme Therapeutics (NASDAQ:HALO) Stock Falls 11.5% - What's Next?

Key Points

• HALO shares fell 11.5% in Friday midday trading despite trading volume running 72% below its daily average.
• Halozyme’s Q3 revenue rose 39% to about $493 million, adjusted EPS of $2.39 beat estimates, and the company raised its 2026 outlook. The FDA also approved a cancer treatment that uses its ENHANZE technology, potentially supporting future royalties.
• Analyst views remain broadly positive, with a “Moderate Buy” consensus, but investors may be weighing guidance details and a Merck patent dispute as risks.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report)'s share price dropped 11.5% during mid-day trading on Friday. The company traded as low as $113.71 and last traded at $108.7720. 535,583 shares traded hands during trading, a decline of 72% from the average daily volume of 1,947,136 shares. The stock had previously closed at $122.96.

Trending Headlines about Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million, while royalty revenue climbed 44% to a record $341 million. Adjusted EPS of $2.39 also exceeded estimates. Halozyme raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Halozyme Q3 results and raised guidance
• Positive Sentiment: The FDA granted accelerated approval for Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalty revenue. FDA approval announcement
• Positive Sentiment: Halozyme said it expects zero to minimal royalty-revenue impact through at least 2035 from the final Medicare drug-price negotiation rule, easing a potential long-term policy concern. Medicare rule impact update
• Positive Sentiment: Citizens JMP raised its price target to $149 and reiterated a market-outperform rating, reflecting optimism about HALO’s prospects. Citizens JMP rating
• Neutral Sentiment: Wells Fargo raised its target to $110 but maintained an equal-weight rating, signaling a more measured view. Wells Fargo rating
• Negative Sentiment: Despite the earnings beat and higher outlook, the market reaction suggests investors may be scrutinizing the guidance changes. The earnings-call coverage also flagged a Merck patent dispute as a risk to monitor. Q3 earnings call highlights

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Benchmark reissued a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Stifel Nicolaus set a $130.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, October 16th. Zacks Research upgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, October 13th. Citizens Jmp raised their target price on shares of Halozyme Therapeutics from $93.00 to $149.00 and gave the stock a "market outperform" rating in a research note on Friday. Finally, TD Cowen raised their target price on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $106.09.

Halozyme Therapeutics Trading Down 14.8%

The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The company has a fifty day simple moving average of $115.26 and a 200-day simple moving average of $84.57. The company has a market capitalization of $11.89 billion, a PE ratio of 31.36, a PEG ratio of 0.49 and a beta of 0.92.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the consensus estimate of $2.30 by $0.09. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The business had revenue of $492.97 million for the quarter, compared to analyst estimates of $491.63 million. During the same quarter in the previous year, the firm earned $1.72 EPS. The company's quarterly revenue was up 39.1% compared to the same quarter last year. Analysts predict that Halozyme Therapeutics, Inc. will post 8.32 EPS for the current year.

Insiders Place Their Bets

In other news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director owned 40,418 shares of the company's stock, valued at $4,154,970.40. This represents a 3.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 18,996 shares of the firm's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the sale, the director owned 58,839 shares of the company's stock, valued at $6,339,313.86. This represents a 24.41% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,852 shares of company stock valued at $13,538,046 over the last ninety days. Company insiders own 2.50% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Horizon Investment Services LLC acquired a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $2,254,000. WINTON GROUP Ltd increased its holdings in shares of Halozyme Therapeutics by 704.6% in the 2nd quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company's stock valued at $4,723,000 after acquiring an additional 52,848 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $1,025,000. Great Lakes Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth about $2,821,000. Finally, Chase Investment Counsel Corp acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth about $2,035,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company's primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.